Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases. Some of the major hematology drugs include Albumin, Epoetin, Zoladex, and Hyskon.
The top five companies covered are Novo Nordisk A/S, Shire Plc., Bayer AG, Daiichi Sankyo Company, Limited and Biogen Inc. Novo Nordisk was the largest company in the hematology drug market in 2017.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
The global hematology drugs market was valued at above $39 billion in 2017. North America was the largest region in the hematology drugs market in 2017, accounting for around 40% market share. The USA was the largest country in the market in 2017, accounting for 32% market share.
Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its cheap price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. In April 2017, WOMAN (World Maternal Antifibrinolytic), an international, randomized, double-blind, placebo-controlled trial including over 20,000 women from 193 hospitals in 21 countries, found that using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%, as compared to placebo.